Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence

Csonka, Tamás; Murnyák, Balázs; Szepesi, Rita; Bencze, János; Bognár, László; Klekner, Álmos; Hortobágyi, Tibor

doi:10.5114/fn.2016.60088

Cited by 27 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunohistochemical (IHC) analysis was carried out as previously described [44]. Briefly, the staining was performed on 4-μm-thick FFPE sections using the manufacturers’ protocols.…”

Section: Methodsmentioning

confidence: 99%

PARP1expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

Overexpression of PARP1 exists in various cancers, including glioblastoma (GBM). Although PARP1 inhibition is a promising therapeutic target, no comprehensive study has addressed PARP1's expression characteristics and prognostic role regarding molecular heterogeneity in astrocytomas including GBM. Our aim was to evaluate PARP1's associations with survival, WHO grade, lineage specific markers, and GBM transcriptomic subtypes. We collected genomic and clinical data from the latest glioma datasets of The Cancer Genome Atlas and performed PARP1, ATRX, IDH1, and p53 immunohistochemistry on GBM tissue samples. We demonstrated that PARP1 gain and increased mRNA expression are characteristics of high-grade astrocytomas, particularly of Proneural and Classical GBM subtypes. Additionally, higher PARP1 levels exhibited an inverse correlation with patient survival (p<0.005) in the Classical subgroup. ATRX (p=0.006), and TP53 (p=0.015) mutations were associated with increased PARP1 expression and PARP1 protein level correlated with ATRX loss and p53 overexpression. Furthermore, higher PARP1 expression together with wildtype TP53 indicated shorter survival (p=0.039). Therefore, due to subtype specificity, PARP1 expression level and TP53 mutation status are reliable marker candidates to distinguish Proneural and Classical subtypes, with prognostic and therapeutic implications in GBM.

show abstract

“…Immunohistochemical (IHC) analysis was carried out as previously described [44]. Briefly, the staining was performed on 4-μm-thick FFPE sections using the manufacturers’ protocols.…”

Section: Methodsmentioning

confidence: 99%

PARP1expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The role of progesterone receptor (PR) has been studied in numerous papers. There is inverse relation between protein expression and tumour grade [25]. While the rate of cell division (mitosis) is increasing with higher grade, meningiomas in pregnancy are predominantly low grade (WHO I) with negligible mitotic activity.…”

Section: Pathophysiological and Morphological Aspectsmentioning

confidence: 99%

Pathophysiology of meningioma growth in pregnancy

et al. 2017

Self Cite

View full text Add to dashboard Cite

AbstractMeningioma is among the most frequent brain tumours predominantly affecting elderly women. Epidemiological studies have shown that at the age of fertility the incidence is relatively low. The biological behaviour of meningioma in pregnancy is different from other meningiomas. The possible explanation is rooted in the complex physiological changes and hormonal differences during pregnancy. The increased meningioma growth observed in pregnancy is presumably the result of endocrine mechanisms. These include increase in progesterone, human placental lactogen (hPL) and prolactin (PRL) serum levels. In contrast, levels of pituitary hormones such as follicle stimulating hormone (FSH), luteinizing hormone (LH) and human chorionic gonadotropin (hCG) produced by the placenta are decreasing in the mother prior to childbirth. Besides, vascular factors also play a crucial role. Peritumoral brain edema (PTBE), with well-known causative association with vascular endothelial growth factor (VEGF), can often be seen both with imaging and in the surgical specimens. Our aim is to assess published research on this topic including diagnostic and therapeutic guidelines, and to provide a clinically useful overview on the pathophysiology and biological behaviour of this rare complication of pregnancy.

show abstract

“…Histological grading in parallel with a panel of immunohistochemistry prognostic markers such as p53, poly(ADP-ribose) polymerase-1 (PARP-1) and Ki-67 serve as independent prognostic indicators to predict recurrence and tumor progression. [17][18][19] Although xanthomatous meningioma is generally considered as a grade I (benign) tumor of the meninges with excellent clinical outcome, as in the present case, in extremely rare occurrences, xanthomatous change within atypical and anaplastic meningiomas have been previously reported. 20 Xanthomatous change in this subtype of meningioma was regarded as a metaplastic process and was categorized as one of the metaplastic meningiomas.…”

Section: Discussionmentioning

confidence: 51%

“…The clinical behavior of xanthomatous meningioma remains unclear due to the rarity of the entity. Histological grading in parallel with a panel of immunohistochemistry prognostic markers such as p53, poly(ADP‐ribose) polymerase‐1 (PARP‐1) and Ki‐67 serve as independent prognostic indicators to predict recurrence and tumor progression . Although xanthomatous meningioma is generally considered as a grade I (benign) tumor of the meninges with excellent clinical outcome, as in the present case, in extremely rare occurrences, xanthomatous change within atypical and anaplastic meningiomas have been previously reported…”

Section: Discussionmentioning

confidence: 53%

Xanthomatous meningioma: A metaplastic or degenerative phenomenon?

2018

View full text Add to dashboard Cite

Xanthomatous changes can be observed in various conditions including primary xanthomatosis that is linked to an underlying hypercholesterolemia and more commonly associated with secondary xanthomatous degenerative processes in neoplasm and chronic inflammation. Meningioma with extensive xanthomatous change is exceedingly rare. The presence of cholesterol clefts within this peculiar meningioma subtype has not been described. Herein, we report an unusual case of xanthomatous meningioma in an 83-year-old normolipidemic woman, who presented to us with worsening lower limb weakness and global aphasia. There was increasing evidence to suggest that the presence of xanthomatous changes in long-standing meningioma is merely a sequela of cellular degeneration rather than true metaplastic change as previously hypothesized. Hence, the diagnosis of "xanthomatous meningioma" in the metaplastic category should be revisited and considered as a distinct histological subtype. The possible histogenesis of such intriguing phenomenon is discussed with a review of the literature.

show abstract

Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence

Abstract: A b s t r a c t Although tumour recurrence is an important and not infrequent event in meningiomas

Cited by 27 publications

References 24 publications

PARP1expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma

PARP1expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma

Pathophysiology of meningioma growth in pregnancy

Xanthomatous meningioma: A metaplastic or degenerative phenomenon?

Contact Info

Product

Resources

About